{"id":3555,"date":"2011-03-14T10:51:35","date_gmt":"2011-03-14T14:51:35","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=3555"},"modified":"2011-03-14T10:51:35","modified_gmt":"2011-03-14T14:51:35","slug":"report-pharma-research-productivity-undercounted","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=3555","title":{"rendered":"Report: Pharma Research Productivity Undercounted"},"content":{"rendered":"

\"Calculator<\/a>In a new analysis, pharmaceutical market research company EvaluatePharma<\/a> in London, U.K. says current methods of measuring productivity of the industry miss a big part of the industry’s output and thus give a misleading picture. The report suggests the pharma industry is in better shape than most observers indicate.<\/p>\n

EvaluatePharma says most industry watchers count the numbers of new drugs approved by the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research<\/a> (CDER), the agency’s main regulator of over-the-counter and prescription drugs. The company claims these counts miss new approvals issued by FDA’s Center for Biologics Evaluation and Research<\/a> (CBER), which includes many blood and vaccine products.<\/p>\n

Last year, says EvaluatePharma, CDER approved 21 new drugs, while CBER approved five biologics<\/a>, raising the total to 26. Among the new biologics approved by CBER were Dendreon’s Provenge, a prostate cancer vaccine, and Pfizer’s pneumococcal vaccine, Prevnar 13. The report calls these two drugs “likely blockbusters.”<\/p>\n

EvaluatePharma points out as well that the pharma industry is getting better at choosing high-value drug targets<\/a>, and while the number of new approvals may be dropping, sales of new drug products remains high. The report found 2010 sales of drugs approved in 2004 reach $11.6 billion. This “class of 2004” drugs include best-sellers such as Avastin, Spiriva, and Lyrica.<\/p>\n

The report indicates that anticipated approval rates in 2011 for biologics and new molecular entities (NMEs) — active ingredients never before marketed in the United States in any form — point to another high-value class of products, as in 2004. EvaluatePharma estimates FDA will approve 23 NMEs and 5 new biologicals in 2011. These rates point to strong fifth-year sales, as occurred with the 2004 class.<\/p>\n

While the overall industry picture may be better than reported, EvaluatePharma notes that the industry still faces challenges from declining R&D productivity and rising costs of drug development.<\/p>\n

Read more. NSF: Companies Investing in R&D Made More Innovations<\/a><\/p>\n

Photo: Jorge Franganillo\/Flickr<\/a><\/p>\n

*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"

In a new analysis, pharmaceutical market research company EvaluatePharma in London, U.K. says current methods of measuring productivity of the industry miss a big part of the industry’s output and thus give a misleading picture. The report suggests the pharma industry is in better shape than most observers indicate. EvaluatePharma says most industry watchers count […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,5],"tags":[31,21,22,27,129],"class_list":["post-3555","post","type-post","status-publish","format-standard","hentry","category-business","category-regulations","tag-biomedical","tag-biotech","tag-fda","tag-pharmaceuticals","tag-statistics"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3555"}],"version-history":[{"count":1,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3555\/revisions"}],"predecessor-version":[{"id":3556,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3555\/revisions\/3556"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}